Plus Therapeutics, Inc. (PSTV)

Plus Therapeutics Stock Forecast

PSTV's stock price has decreased by -67.61% in the past year and price targets may not have had time to catch up.

Stock Price Forecast

The 3 analysts that cover Plus Therapeutics stock have a consensus rating of "Strong Buy" and an average price target of $55, which forecasts a 758.03% increase in the stock price over the next year. The lowest target is $25 and the highest is $75.

Price Target: $55 (+758.03%)

Analyst Consensus: Strong Buy

Target	Low	Average	Median	High
Price	$25	$55	$65	$75
Change	+290.02%	+758.03%	+914.04%	+1070.0%

Analyst Ratings

The average analyst rating for Plus Therapeutics stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.

Recommendation Trends

Rating	Nov '25	Dec '25	Jan '26	Feb '26	Mar '26	Apr '26
Strong Buy	4	4	4	4	3	3
Buy	0	0	0	0	0	0
Hold	0	0	0	0	1	1
Sell	0	0	0	0	0	0
Strong Sell	0	0	0	0	0	0
Total	4	4	4	4	4	4

Latest Forecasts

Analyst	Firm	Rating	Rating	Action	Price Target	Upside	Date
Edward Woo Ascendiant Capital	Ascendiant Capital	Strong Buy Maintains $475 → $65	Strong Buy	Maintains	$475 → $65	+914.04%	Apr 9, 2026
Jason Kolbert D. Boral Capital	D. Boral Capital	Strong Buy → Hold Downgrades n/a	Strong Buy → Hold	Downgrades	n/a	n/a	Mar 31, 2026
Jason Kolbert D. Boral Capital	D. Boral Capital	Strong Buy Maintains $75	Strong Buy	Maintains	$75	+1,070.05%	Mar 19, 2026
Sean Lee HC Wainwright & Co.	HC Wainwright & Co.	Strong Buy Maintains $50 → $25	Strong Buy	Maintains	$50 → $25	+290.02%	Jan 23, 2026
Jason Kolbert D. Boral Capital	D. Boral Capital	Strong Buy Maintains $125 → $100	Strong Buy	Maintains	$125 → $100	+1,460.06%	Jan 22, 2026

More Analyst Ratings

Financial Forecast

Revenue This Year

5.90M

Increased by 13.20%

from 5.21M

Revenue Next Year

21.33M

Increased by 261.48%

from 5.90M

EPS This Year

-3.70

from -7.25

EPS Next Year

-2.17

from -3.70

Fiscal Year	FY 2021	FY 2022	FY 2023	FY 2024	FY 2025	FY 2026	FY 2027
Period Ending	Dec 31, 2021	Dec 31, 2022	Dec 31, 2023	Dec 31, 2024	Dec 31, 2025	Dec 31, 2026	Dec 31, 2027
Revenue	-	224.00K	4.91M	5.82M	5.21M	5.90M	21.33M
Revenue Growth	-	-	2,093.30%	18.54%	-10.49%	13.20%	261.48%
EPS	-416.25	-289.58	-106.00	-58.52	-7.25	-3.70	-2.17
EPS Growth	-	-	-	-	-	-	-
Forward PE	-	-	-	-	-	-	-
No. Analysts	-	-	-	-	-	7	6

Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.

Revenue Forecast

Revenue	2026	2027	2028	2029	2030	2031	2032	2033
High	11.9M	29.4M
Avg	5.9M	21.3M
Low	3.9M	9.8M

Revenue Growth

Revenue Growth	2026	2027	2028	2029	2030	2031	2032	2033
High	127.6%	398.2%
Avg	13.2%	261.5%
Low	-24.8%	66.1%

EPS Forecast

EPS	2026	2027	2028	2029	2030	2031
High	-2.89	-1.84
Avg	-3.70	-2.17
Low	-4.66	-2.45

EPS Growth

EPS Growth	2026	2027	2028	2029	2030	2031
High	-	-
Avg	-	-
Low	-	-

Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.